London
Roots Analysis has announced theaddition of “Live Biotherapeutic Products and Microbiome ContractManufacturing Market, 2020-2030: Focus on ActivePharmaceutical Ingredients and Finished Dosage Forms, 2020-2030” report to itslist of offerings.
Manufacturing livebiotherapeutic products is both technically challenging and financiallydemanding; as a result, innovator firms are becoming increasingly reliant oncontract service providers to access specialized facilities and optimizeoverall costs.
Toorder this 300+ page report, which features 140+ figures and 125+ tables,please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
Key Market Insights
Over 25 players claimto provide microbiome-based live biotherapeutics contract manufacturing
More than 80% of the companiesengaged in this domain are mid-sized and large firms; examples of firms established in 2019 include Arranta Bio and BacThera(a Lonza and Chr. Hansen joint venture). Further, nearly 50% of the CMOshave established the necessary expertise for handling both anaerobic andaerobic strains.
35+ manufacturing facilitiesfocused on live biotherapeutics have been established worldwide
Majority (~55%) of themanufacturing facilities are located in Europe, followed by North America. Prominent manufacturing hubsin the Europe include (in decreasing order of number of manufacturingfacilities) the UK,France, the Netherlands, Italy, Germany, Switzerland, and Sweden.
Approximately 88% of thetotal installed capacity is dedicated to commercial scale manufacturing
Whereas, rest (~10%) of the capacity is being used for preclinical / clinicalscale manufacturing of microbiome products. In addition, over 60% of the totalcurrent global, installed manufacturing capacity is installed in Europe.
Over 170 registeredclinical trials involved the use of microbiome-based live biotherapeutics
Majority of these studies arebeing conducted at various hospitals / centers across the US. Examples ofleading non-industry players include (in decreasing order of number oftrials) University of California, National Institute of Allergy andInfectious Diseases, Radboud University, and The University of Texas HealthScience Center.
The global clinical demandfor microbiome-based live biotherapeutic products is anticipated to grow at a CAGR of 23%,between 2020 and 2030
By 2030, over 31,000 patientsare estimated to be enrolled in the clinical trials involving the use ofmicrobiome-based live biotherapeutics. Industry players are anticipated tocontribute majority (over 60%) of the demand in the short-term as well aslong-term.
Several big pharma players areactively engaged in the microbiome live biotherapeutics domain
In fact, leadingpharmaceutical companies have partnered with smaller business entities todevelop manufacturing capabilities related to microbiome-based therapies /diagnostics. Examples of such small ventures with players with in-housecapability include (in alphabetical order) Assembly Biosciences,Enterome Bioscience, Finch Therapeutics and NuBiyota.
By 2030, North America and Europe are anticipated tocapture over 85% of the market opportunity
Interms of type of product manufactured, APIs currently represent the highestshare (58%); this trend is unlikely to change in the foreseen future.
To request a samplecopy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/306/request-sample.html
The USD 300 million (by 2030) financial opportunitywithin the microbiome contract manufacturing market has been analysed acrossthe following segments:
§ Typeof Product Manufactured
§ ActivePharmaceutical Ingredients (APIs)
§ FinishDrug Formulations (FDFs)
§ Typeof Type of Formulation
§ SolidFormulations
§ OralLiquids
§ Injectables
§ Others
§ Scaleof Operation
§ Clinical
§ Commercial
§ CompanySize
§ Small-sized
§ Mid-sized
§ Large
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ Asia-Pacificand Rest of the World
The report featuresinputs from eminent industry stakeholders, according to whom the microbiometherapeutics contract manufacturing services market is likely to witnesssubstantial growth in the foreseen future. The report includes detailedtranscripts of discussions held with the following experts:
The research coversdetailed profiles brief profiles of several companies (including thoselisted below); each profile features an overview of the company, itsfinancial information (if available),microbiome-related service portfolio, facilities dedicated to microbiomemanufacturing, and an informed future outlook.
§ Biose®
§ BJPLaboratories
§ Capsugel(acquired by Lonza)
§ Cerbios-Pharma
§ CobraBiologics (acquired Cognate Bioservices)
§ InpacProbiotics
§ Paragon Bioservices (a unit of Catalent Biologics)
§ UASLabs
For additionaldetails, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html oremail sales@rootsanalysis.com
You may also beinterested in the following titles:
1. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
2. Antibody Contract Manufacturing Market, 2020 – 2030
3. The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targetingdrugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
